ES2166817T3 - Mejora de la tolerancia a la glucosa. - Google Patents

Mejora de la tolerancia a la glucosa.

Info

Publication number
ES2166817T3
ES2166817T3 ES95909382T ES95909382T ES2166817T3 ES 2166817 T3 ES2166817 T3 ES 2166817T3 ES 95909382 T ES95909382 T ES 95909382T ES 95909382 T ES95909382 T ES 95909382T ES 2166817 T3 ES2166817 T3 ES 2166817T3
Authority
ES
Spain
Prior art keywords
glucose tolerance
improvement
monohydrate
cyclobutyl
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95909382T
Other languages
English (en)
Spanish (es)
Inventor
Ramon Vargas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Knoll Pharmaceutical Co
Original Assignee
Knoll Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22703362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2166817(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Knoll Pharmaceutical Co filed Critical Knoll Pharmaceutical Co
Application granted granted Critical
Publication of ES2166817T3 publication Critical patent/ES2166817T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES95909382T 1994-02-03 1995-02-03 Mejora de la tolerancia a la glucosa. Expired - Lifetime ES2166817T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/190,924 US5459164A (en) 1994-02-03 1994-02-03 Medical treatment

Publications (1)

Publication Number Publication Date
ES2166817T3 true ES2166817T3 (es) 2002-05-01

Family

ID=22703362

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95909382T Expired - Lifetime ES2166817T3 (es) 1994-02-03 1995-02-03 Mejora de la tolerancia a la glucosa.

Country Status (17)

Country Link
US (2) US5459164A (https=)
EP (1) EP0814788B1 (https=)
JP (1) JPH10503166A (https=)
KR (1) KR100339874B1 (https=)
CN (1) CN1070698C (https=)
AT (1) ATE205390T1 (https=)
AU (1) AU694761B2 (https=)
CA (1) CA2182620C (https=)
DE (1) DE69522716T2 (https=)
DK (1) DK0814788T3 (https=)
ES (1) ES2166817T3 (https=)
IL (1) IL112515A (https=)
PH (1) PH31220A (https=)
PT (1) PT814788E (https=)
TW (1) TW314466B (https=)
WO (1) WO1995020949A1 (https=)
ZA (1) ZA95814B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
AU3757800A (en) * 1999-03-19 2000-10-09 Abbott Gmbh & Co. Kg Method of controlling weight gain associated with therapeutic drugs
WO2000056321A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
WO2000056309A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Method of treating sexual dysfunction
AU3894500A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Prevention of cardiovascular disease
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
JP2002539252A (ja) * 1999-03-19 2002-11-19 クノール・ゲー・エム・ベー・ハー 胆石の治療
US6803387B1 (en) * 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US6403650B1 (en) * 1999-03-19 2002-06-11 Knoll Pharmaceutical Company Treatment of pulmonary hypertension
EP1169029B1 (en) * 1999-03-19 2005-05-04 Abbott GmbH & Co. KG Use of sibutramine or its derivative for the treatment of sleep disorders
WO2000056319A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
IL145238A0 (en) * 1999-03-19 2002-06-30 Knoll Gmbh Treatment of osteoarthritis
WO2000056311A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Control of metabolism
AU3896900A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of pain
WO2000056310A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
US6372797B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of menstrual function
MXPA01009470A (es) * 1999-03-19 2004-03-19 Knoll Gmbh Tratamiento de ciertos canceres asociados con el aumento de peso.
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9926251D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Pharmaceutical formulation
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
JP4278652B2 (ja) * 2002-10-05 2009-06-17 ハンミ ファーム． シーオー．， エルティーディー． 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
WO2006073292A1 (en) 2005-01-06 2006-07-13 Cj Corporation Inorganic acid salts of sibutramine
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
DE3883606T2 (de) * 1987-05-04 1994-01-20 Lilly Co Eli Verwendung von Fluoxetin zur Behandlung des Diabetes.
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Also Published As

Publication number Publication date
JPH10503166A (ja) 1998-03-24
ZA95814B (en) 1995-08-03
AU1736295A (en) 1995-08-21
IL112515A (en) 2000-07-26
AU694761B2 (en) 1998-07-30
CA2182620C (en) 2007-01-16
PH31220A (en) 1998-05-05
CN1144479A (zh) 1997-03-05
EP0814788A4 (en) 1999-05-06
IL112515A0 (en) 1995-12-08
CN1070698C (zh) 2001-09-12
TW314466B (https=) 1997-09-01
US5459164A (en) 1995-10-17
WO1995020949A1 (en) 1995-08-10
EP0814788B1 (en) 2001-09-12
ATE205390T1 (de) 2001-09-15
DE69522716D1 (de) 2001-10-18
PT814788E (pt) 2002-03-28
US5942549A (en) 1999-08-24
CA2182620A1 (en) 1995-08-10
DK0814788T3 (da) 2001-11-19
KR100339874B1 (ko) 2002-11-22
DE69522716T2 (de) 2002-05-29
EP0814788A1 (en) 1998-01-07

Similar Documents

Publication Publication Date Title
ES2166817T3 (es) Mejora de la tolerancia a la glucosa.
CA2266401A1 (en) Use of sibutramine analogues to prevent the development of diabetes
CA2367666A1 (en) Method of treating eating disorders
IE863102L (en) N,n,1,3-tetrasubstituted butylamine derivative.
GB9619961D0 (en) Medical treatment
AU8170094A (en) Substituted 1-oxo-1,2-dihydroisoquinolinoylguanidines and 1,1-dioxo-2H-1,2-benzothiazinoylguanidines, a process for their preparation, their use as medicament or diagnostic agent, and also a medicament containing them
KR960007592A (ko) 신규한 피롤로카바졸
BG103278A (en) Medicamentous treatment
WO2000056315A8 (en) Treatment of pain
KR920016089A (ko) 제i형 당뇨병의 치료방법
CA2022653A1 (en) Dampening solution for lithographic printing
CA2248794A1 (en) Medicament for preventive and treatment for viral infectious diseases
KR970061248A (ko) 알츠하이머병 치료용 1, 1, 2-트리페닐부트-1-엔 유도체
MXPA01009461A (es) Tratamiento de osteoartritis.
RU93004984A (ru) Фармацевтическая композиция на основе 5(2-хлор-1-гидроксиэтил)-4-метилтиазола, применение 5-(2-хлор-1-гидроксиэтил)-4-метил-тиазола для лечения, способ лечения, соли 5-(2-хлор-1-гидроксиэтил)-4-метилтиазола
PT86610A (pt) Process for the preparation of a fungicidal compound containing 1-aminoethyl-3-aryl-4-cyano-pyrroles
CA2156764A1 (en) Process for the preparation of the (-)-n-methyl-n-[4-(4-phenyl-4-acetylaminopiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]benzamine and its pharmaceutically acceptable salts
ES2191022T3 (es) Utilizacion de derivados de la tetrahidropiridina para la preparacion de medicamentos cardioprotectores.
MXPA01009465A (es) Perdida de peso despues del embarazo.
KR950000704A (ko) 로라카베프 하이드로클로라이드 c_1-c_3 알콜 용매화물 및 그의 용도
CA2388176A1 (en) Therapeutic agent for eating disorders
WO2000056316A8 (en) Treatment of gallstones
BG106000A (en) Treatment of hiatial hernia
IT1230367B (it) Visualizzatore di immagini a densita' non uniforme, particolarmente per applicazioni medicali.
RU98113788A (ru) Соединения, имеющие свойства высвобождения гормона роста